232 related articles for article (PubMed ID: 35017665)
21. The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.
de Castro RO; Previato L; Goitea V; Felberg A; Guiraldelli MF; Filiberti A; Pezza RJ
J Biol Chem; 2017 May; 292(20):8459-8471. PubMed ID: 28381560
[TBL] [Abstract][Full Text] [Related]
22. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
23. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.
Xing T; Li L; Chen Y; Ju G; Li G; Zhu X; Ren Y; Zhao J; Cheng Z; Li Y; Xu D; Liang J
Cell Rep Med; 2023 Nov; 4(11):101264. PubMed ID: 37939712
[TBL] [Abstract][Full Text] [Related]
24. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
[TBL] [Abstract][Full Text] [Related]
25. Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma.
Unfried JP; Marín-Baquero M; Rivera-Calzada Á; Razquin N; Martín-Cuevas EM; de Bragança S; Aicart-Ramos C; McCoy C; Prats-Mari L; Arribas-Bosacoma R; Lee L; Caruso S; Zucman-Rossi J; Sangro B; Williams G; Moreno-Herrero F; Llorca O; Lees-Miller SP; Fortes P
Cancer Res; 2021 Oct; 81(19):4910-4925. PubMed ID: 34321241
[TBL] [Abstract][Full Text] [Related]
26. ARID2 Chromatin Remodeler in Hepatocellular Carcinoma.
Loesch R; Chenane L; Colnot S
Cells; 2020 Sep; 9(10):. PubMed ID: 32977645
[TBL] [Abstract][Full Text] [Related]
27. Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining.
Stanlie A; Yousif AS; Akiyama H; Honjo T; Begum NA
Mol Cell; 2014 Jul; 55(1):97-110. PubMed ID: 24954901
[TBL] [Abstract][Full Text] [Related]
28. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma.
Tang L; Chen R; Xu X
Cancer Lett; 2020 Apr; 476():120-128. PubMed ID: 32070778
[TBL] [Abstract][Full Text] [Related]
29. Remodeling and spacing factor 1 (RSF1) deposits centromere proteins at DNA double-strand breaks to promote non-homologous end-joining.
Helfricht A; Wiegant WW; Thijssen PE; Vertegaal AC; Luijsterburg MS; van Attikum H
Cell Cycle; 2013 Sep; 12(18):3070-82. PubMed ID: 23974106
[TBL] [Abstract][Full Text] [Related]
30. BRD4 promotes resection and homology-directed repair of DNA double-strand breaks.
Barrows JK; Lin B; Quaas CE; Fullbright G; Wallace EN; Long DT
Nat Commun; 2022 May; 13(1):3016. PubMed ID: 35641523
[TBL] [Abstract][Full Text] [Related]
31. ZMYM2 restricts 53BP1 at DNA double-strand breaks to favor BRCA1 loading and homologous recombination.
Lee D; Apelt K; Lee SO; Chan HR; Luijsterburg MS; Leung JWC; Miller KM
Nucleic Acids Res; 2022 Apr; 50(7):3922-3943. PubMed ID: 35253893
[TBL] [Abstract][Full Text] [Related]
32. Reptin regulates DNA double strand breaks repair in human hepatocellular carcinoma.
Raymond AA; Benhamouche S; Neaud V; Di Martino J; Javary J; Rosenbaum J
PLoS One; 2015; 10(4):e0123333. PubMed ID: 25875766
[TBL] [Abstract][Full Text] [Related]
33. The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Apr; 53(4):e12791. PubMed ID: 32162380
[TBL] [Abstract][Full Text] [Related]
34. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
35. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
36. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
37. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.
Wang J; McGrail DJ; Bhupal PK; Zhang W; Lin KY; Ku YH; Lin T; Wu H; Tsai KC; Li K; Peng CY; Finegold MJ; Lin SY; Tsai RYL
Mol Cancer Res; 2020 May; 18(5):723-734. PubMed ID: 32051231
[TBL] [Abstract][Full Text] [Related]
38. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.
Li M; Zhao H; Zhang X; Wood LD; Anders RA; Choti MA; Pawlik TM; Daniel HD; Kannangai R; Offerhaus GJ; Velculescu VE; Wang L; Zhou S; Vogelstein B; Hruban RH; Papadopoulos N; Cai J; Torbenson MS; Kinzler KW
Nat Genet; 2011 Aug; 43(9):828-9. PubMed ID: 21822264
[TBL] [Abstract][Full Text] [Related]
39. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma.
Zhou J; Li W; Guo J; Li G; Chen F; Zhou J
Tumour Biol; 2016 Mar; 37(3):3561-9. PubMed ID: 26456956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
